Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05928585 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers
A Phase 1 study of Immune System Diseases and Autoimmunity, sponsored by HI-Bio, A Biogen Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05928585 is a Phase 1 study of Immune System Diseases and Autoimmunity that has completed, run by HI-Bio, A Biogen Company. The registered enrollment target is 30 participants, below the 151-participant average among 18 other Immune System Diseases trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05928585, a Phase 1 study of Immune System Diseases and Autoimmunity, has completed, sponsored by HI-Bio, A Biogen Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test safety of the investigational product in healthy volunteers. The main questions it aims to answer is when HIB210 is administered as multiple doses, is it: 1. Safe 2. Well tolerated 3. Does the body absorb and eliminate HIB210 as expected
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HIB210
Study Locations (1)
Florida
- HI-Bio Investigational Site - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05928585
The ClinicalTrials.gov registry entry for NCT05928585 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 18 other Immune System Diseases trials with a reported enrollment target (80% lower). The listed sponsor is HI-Bio, A Biogen Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05928585 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05928585 about?
NCT05928585 is a clinical study titled "A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers". The goal of this clinical trial is to test safety of the investigational product in healthy volunteers. The main questions it aims to answer is when HIB210 is administered as multiple doses, is it: 1. Safe 2. Well tolerated 3. Does the body absorb and eliminate HIB210 as expected
What is the current status of trial NCT05928585?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-06. Estimated completion is 2024-06-10.
What conditions does trial NCT05928585 study?
This clinical trial studies the following conditions: Immune System Diseases, Autoimmunity.
What interventions are being tested in trial NCT05928585?
The interventions under investigation include: Placebo (DRUG), HIB210 (DRUG).
Who is sponsoring clinical trial NCT05928585?
This trial is sponsored by HI-Bio, A Biogen Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05928585 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
ACTIVE NOT RECRUITING · Phase 1
-
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.